The value-relevance of advertising: evidence from pharmaceutical industry

Journal of Accounting, Auditing and Finance

Volumn 25, Issue 1, 2010, Pages 85-120

  Gu, Feng ^a   Li, John Q ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 76649102771     PISSN: 0148558X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148558X1002500104     Document Type: Article

References (106)

1. AAA (American Accounting Association), FASC (Financial Accounting Standards Committee). 2002. "Recommendations on Disclosure of Nonfinancial Performance Measures." Accounting Horizons 16 (4): 353-362.
2. AAA (American Accounting Association), FASC (Financial Accounting Standards Committee). 2003. "Implications of Accounting Research for the FASB's Initiatives on Disclosure of Information about Intangible Assets." Accounting Horizons 17 (2): 175-185.
3. Abdel-Khalik, A. 1975. "Advertising Effectiveness and Accounting Policy." Accounting Review 50 (4): 657-670.
4. Aboody, D., and B. Lev. 1998. "The Value Relevance of Intangibles: The Case of Software Capitalization." Journal of Accounting Research 36 (supplement): 161-191. (Pubitemid 128665979)
5. Adams, W., and J. Yellen. 1977. "What Makes Advertising Profitable?" The Economic Journal 87 (347): 427-449.
6. Almasi, E. 2006. "The Relation between Direct-to-Consumer Prescription Drug Advertising and Prescription Rates." Working Paper, Stanford University.
7. Amir, E., Y. Guan, and G. Livne. 2006. "The Association of R&D and Capital Expenditures with Subsequent Earnings Variability." Journal of Business Finance and Accounting 34 (1 & 2): 222-246.
8. Baber, W., P. Fairfield, and J. Haggard. 1991. "The Effect of Concern about Reported Income on Discretionary Spending Decisions: The Case of Research and Development." The Accounting Review 66 (4): 818-829.
9. Barney, J. 1991. "Firm Resources and Sustained Competitive Advantage." Journal of Management 17 (1): 99-120.
10. Barth, M., M. Clement, G. Foster, and R. Kasznik. 1998. "Brand Values and Capital Market Valuation." Review of Accounting Studies 3: 41-68.
11. Bell, R., R. Kravitz, and M. Wilkes. 1999. "Direct-to-Consumer Prescription Drug Advertising and the Public." Journal of General Internal Medicine 14: 651-657.
12. Bens, D., V. Nagar, and M. Wong. 2002. "Real Investment Implications of Employee Stock Option Exercises." Journal of Accounting Research 40 (2): 359-393. (Pubitemid 36256444)
13. Berndt, E. 1990. The Practice of Econometrics: Classic and Contemporary. Reading, MA: AddisonWesley Publishing Company.
14. Bhattacharya, J., and W. Vogt. 2003. "A Simple Model of Pharmaceutical Price Dynamics." Journal of Law and Economics 46: 599-626. (Pubitemid 38260115)
15. Bloch, F., and D. Manceau. 1999. "Persuasive Advertising in Hotelling's Model of Product Differentiation." International Journal of Industrial Organization 17: 557-574. (Pubitemid 129639727)
16. Brown, S., and J. Warner. 1985. "Using Daily Stock Returns: The Case of Event Studies." Journal of Financial Economics 14 (1): 3-31.
17. Bublitz, B., and M. Ettredge. 1989. "The Information in Discretionary Outlays: Advertising, Research and Development." Accounting Review 64 (1): 108-124.
18. Bushee, B. 1998. "The Influence of Institutional Investors on Myopic R&D Investment Behavior." The Accounting Review 73 (3): 305-333. (Pubitemid 128182951)
19. Cabral, L. 2000. Introduction to Industrial Organization. Cambridge, MA: MIT Press.
20. Chan, K., J. Lakonishok, and T. Sougiannis. 2001. "The Stock Market Valuation of Research and Development Expenditures." Journal of Finance 56: 2431-2456. (Pubitemid 33585028)
21. Chan, S., J. Kesinger, and J. Martin. 1992. "The Market Rewards Promising R&D and Punishes the Rest." Journal of Applied Corporate Finance 5 (1): 59-66.
22. Chauvin, K., and M. Hirschey. 1994. "Advertising, R&D Expenditures and the Market Value of the Firm." Financial Management 22: 128-140.
23. Cohen, W., and R. Levin. 1989. "Empirical Studies of Innovation and Market Structure." In Handbook of Industrial Organization, ed. R. Schmalensee and R. Willig. Amsterdam: North Holland.
24. Collins, D., and S. P. Kothari. 1989. "An Analysis of Intertemporal and Cross-sectional Determinants of Earnings Response Coefficients." Journal of Accounting and Economics 11: 143-181.
25. Coscelli, A. 2000. "The Importance of Doctors' and Patients' Preferences in the Prescription Decision." Journal of Industrial Economics 48: 349-369.
26. Darrough, M., and S. Rangan. 2005. "Do Managers Manipulate R&D Spending When They Sell Their Shares in an Initial Public Offering?" Journal of Accounting Research 43 (1): 1-33. (Pubitemid 40344777)
27. Dechow, P., and R. Sloan. 1991. "Executive Incentives and Horizon Problem: An Empirical Investigation." Journal of Accounting and Economics 14 (1): 51-89.
28. Dechow, P., S. Richardson, and R. Sloan. 2008. "The Persistence and Pricing of the Cash Component of Earnings." Journal of Accounting Research 46 (3): 537-566.
29. Deng, Z., B. Lev, and F. Narin. 1999. "Science and Technology as Predictors of Stock Performance." Financial Analysts Journal 55: 20-32.
30. Dekimpe, M., and D. Hanssens. 1995. "The Persistence of Marketing Effects on Sales." Marketing Science 14 (Winter): 1-21.
31. Demers, E., and B. Lev. 2001. "A Rude Awakening: Internet Value Drivers in 2000." Review of Accounting Studies 6: 331-359.
32. Dikolli, S., W. Kinney, K. Sedatole. 2007. "Measuring Customer Relation Value: The Role of Switching Cost." Contemporary Accounting Research 24 (1): 93-132.
33. Donohue, J., E. Berndt, and M. Rosenthal. 2004. "Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for Depression." Medical Care 42 (12): 1176-1185. (Pubitemid 39627294)
34. Donohue, J., Cevasco, M., and M. Rosenthal. 2007. "A Decade of Direct-to-Consumer Advertising of Prescription Drugs." New England Journal of Medicine 357: 673-681. (Pubitemid 47267237)
35. Economist. 2007. "From Bench to Bedside: A Reform of American Regulation Would Better Drugs for Everybody." (June 28): 14-16.
36. Erickson, G., and R. Jacobson. 1992. "Gaining Comparative Advantage through Discretionary Expenditures: The Return to R&D and Advertising." Management Science 38 (9): 1264-1279.
37. Fama, E., and J. MacBeth. 1973. "Risk, Return, and Equilibrium-Empirical Tests." Journal of Political Economy 81: 607-636.
38. FASB (Financial Accounting Standards Board). 1985. Statement of Financial Accounting Standards (SFAS) No.86. Accounting for the Costs of Computer Software to Be Sold, Leased, or Otherwise Marketed. Norwalk, CT: FASB.
39. GAO (Government Accounting Office). 2006. "Prescription Drugs: Improvements Needed in FDA's Oversight of Direct-to-Consumer Advertising." Washington, DC: GAO.
40. Graham, R., and K. Frankenberger. 2000. "The Contribution of Changes in Advertising Expenditures to Earnings and Market Value." Journal of Business Research 50: 149-155.
41. Graham, J., R. Harvey, and S. Rajgopal. 2005. "The Economic Implications of Corporate Financial Reporting." Journal of Accounting and Economics 40 (1-3): 3-73. (Pubitemid 41614936)
42. Greuner, M., D. Kamerschen, and P. Klein. 2000. "The Competitive Effects of Advertising in the US Automobile Industry, 1970-1994." International Journal of the Economics of Business 7 (3): 245-261.
43. Grossman, G., and C. Shapiro. 1984. "Informative Advertising with Differentiated Products." Review of Economic Studies 51: 63-81.
44. Gu, F. 2005. "Innovation, Future Earnings, and Market Efficiency." Journal of Accounting, Auditing, and Finance 20 (4): 385-418. (Pubitemid 43198704)
45. Gu, F., and B. Lev. 2002. "On the Relevance and Reliability of R&D." Working paper, Stem School of Business, New York University.
46. Gu, F., and B. Lev. 2003. "Intangible Assets: Measurement, Drivers, and Usefulness." Working paper, Stern School of Business, New York University.
47. Hall, B. 1993. "The Stock Market's Valuation of R&D Investment during the 1980's." American Economic Review 83: 259-264.
48. Hansen, Z., and M. Law. 2004. "The Political Economy of Truth-in-Advertising' Regulation during the Progressive Era." Working paper, Washington University.
49. Hanssens, D., L. Parsons, and R. Schultz. 2001. Market Response Models: Econometric and Timeseries Analysis. Boston, MA: Kluwer Academic Press.
50. Healy, P., S. Myers, and C. Howe. 2002. "R&D Accounting and the Tradeoff between Relevance and Objectivity." Journal of Accounting Research 40: 677-710.
51. Heitzman, S., C. Wasley, and J. Zimmerman. 2008. "The Joint Effects of Materiality Thresholds and Voluntary Disclosure Incentives on Firms' Disclosure Decisions." Working paper, University of Rochester.
52. Henderson, D., and C. Hooper. 2007. "Our Lawless FDA." Wall Street Journal, March, 17, A21.
53. Hirschey, M. 1982. "Intangible Capital Aspects of Advertising and R&D Expenditures" Journal of Industrial Economics 30 (4): 375-390.
54. Hirschey, M., and J. Weygandt. 1985. "Amortization Policy for Advertising and Research and Development Expenditure." Journal of Accounting Research 23: 326-335.
55. Hurwitz, M., and R. Caves. 1988. "Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals." Journal of Law and Economics 31 (2): 299-320.
56. Iizuka, T., and G. Jin. 2005. "The Effect of Prescription Drug Advertising on Doctor Visits." Journal of Economics and Management Strategy 14 (3): 701-727.
57. Institute of Medicine. 2006. "The Future of Drug Safety: Promoting and Protecting the Health of the Public." September.
58. Ittner, C., and D. Larcker. 1998. "Are Nonfinancial Measures Leading Indicators of Financial Performance? An Analysis of Customer Satisfaction." Journal of Accounting Research 36: 1-46.
59. Kothari, S. P., T. Laguerre, and A. Leone. 2002. "Capitalization versus Expensing: Evidence on the Uncertainty of Future Earnings from Capital Expenditures versus R&D Outlays." Review of Accounting Studies 7 (4): 355-382.
60. Kravitz, R., R. Epstein, and M. Feldman. 2005. "Influence of Patients' Requests for Direct-toConsumer Advertised Antidepressants." Journal of the American Medical Association 29 (16): 1995-2002.
61. Lang, M., and R. Lundholm. 1996. "Corporate Disclosure Policy and Analyst Behavior." Accounting Review 71: 467-492. (Pubitemid 126149869)
62. Leffler, K. 1981. "Persuasion or Information? The Economics of Prescription Drug Advertising." Journal of Law and Economics 24: 45-74. (Pubitemid 11032026)
63. Lev, B. 2001. Intangibles: Management, Measurement, and Reporting. Washington, DC: Brookings Institution Press.
64. Lev, B., and T. Sougiannis. 1996. "The Capitalization, Amortization, and Value Relevance of R&D." Journal of Accounting and Economics 21: 107-138.
65. Lev, B., and P. Zarowin. 1999. "The Boundaries of Financial Reporting and How to Extend Them." Journal of Accounting Research 37: 353-385.
66. Lev, B., and S. Radhakrishnan. 2005. "The Valuation of Organization Capital." In Measuring Capital in a New Economy, ed. Corrado, Haltiwanger, and Sichel. Chicago, IL: National Bureau of Economic Research and University of Chicago Press.
67. Lev, B., B. Sarath, and T. Sougiannis. 2005. "R&D Reporting Biases and Their Consequences." Contemporary Accounting Research 22 (4): 977-1026.
68. Lexchin, J., and B. Mintzes. 2002. "Direct-to-Consumer Advertising of Prescription Drugs: The Evidence Says No." Journal of Public Policy and Marketing 21 (3): 194-201.
69. Lilien, G., P. Kotler, and K. Moorthy. 1992. Marketing Models. Englewood, NJ: Prentice Hall.
70. Lipe, R. 1986. "The Information Contained in the Components of Earnings." Journal of Accounting Research 24: 37-64.
71. MacKinlay, A. 1997. "Event Studies in Economics and Finance." Journal of Economic Literature 35 (1): 13-39.
72. Mansfield, E. 1986. "Patents and Innovation: An Empirical Study." Management Science 32 (1): 173-181.
73. Mansfield, E., M. Schwartz, and S. Wagner. 1981. "Imitation Costs and Patents: An Empirical Study." Economic Journal 91: 907-918.
74. Mathews, A., and S. Kang. 2007. "Media Industry Helped Drug Firms Fight Ad Restraints." Wall Street Journal (September 21): B1.
75. Medical Marketing and Media. 2004. "DTC Advertising Gets the Green Light." April.
76. Merrill, R. 1996. "The Architecture of Government Regulation of Medical Products" Virginia Law Review 82 (8): 1753-1866. (Pubitemid 127064078)
77. Mikkelson, W., and M. Partch. 1986. "Valuation Effects of Security Offerings and the Issuance Process." Journal of Financial Economics 15 (1/2): 31-60.
78. Murray, E, B. Lo, L. Pollack, K. Donelan, and K. Lee. 2004. "Direct-to-Consumer Advertising: Public Perceptions of Its Effects on Health Behaviors, Health Care, and Doctor-Patient Relationship." Journal of the American Board of Family Practice 17: 6-18.
79. Neff, J. 2004. "TV Ads Weak Sell for Maturing Goods." Television Week 23 (22): 46.
80. Newey, W., and K. West. 1987. "A Simple, Positive Semi-definite, Heteroskedasticity and Autocorrelation Consistent Covariance Matrix." Econometrica 55 (3): 703-708.
81. Oswald, D., and P. Zarowin. 2007. "Capitalization vs. Expensing of R&D and Earnings Management." Working paper, London Business School and New York University.
82. Peles, Y. 1971. "Economics of Scale in Advertising Beer and Cigarettes." Journal of Business 44 (1): 32-37.
83. Perry, S., and R. Grinaker. 1994. "Earnings Expectations and Discretionary Research and Development Expenditures." Accounting Horizons 8 (4): 43-51.
84. Peterson, M. 2006. "Estimating Standard Errors in Finance Panel Data Sets: Comparing Approaches." Working paper, Northwestern University and NBER.
85. Picconi, M. 1977. "A Reconsideration of the Recognition of Advertising Assets on Financial Statements." Journal of Accounting Research 15 (2): 317-326.
86. Pinto, M., J. Pinto, and J. Barber. 1998. "The Impact of Pharmaceutical Direct Advertising: Opportunities and Obstructions." Health Marketing Quarterly 154: 89-101.
87. Rajgopal, S., M. Venkatachalam, and S. Kotha. 2003. "The Value Relevance of Network Advantages: The Case of E-Commerce Firms." Journal of Accounting Research 41: 135-141.
88. Richard, O., and L. Horn. 2004. "Persistence in Prescriptions of Branded Drugs." International Journal of Industrial Organization 22: 523-540.
89. Rizzo, J. 1999. "Advertising and Competition in the Ethical Pharmaceutical Industry: The Case of Antihypertensive Drugs." Journal of Law and Economics 42: 89-116.
90. Rosenthal, M., B. Emst, J. Donohue, A. Epstein, and R. Frank. 2003. "Demand Effects of Recent Changes in Prescription Drug Promotion." Menlo Park, CA: Kaiser Family Foundation.
91. Roth, M. 1996. "Patterns in Direct-to-Consumer Prescription Drug Print Advertising and Their Public Policy Implications." Journal of Public Policy and Marketing 15: 63-75. (Pubitemid 126315633)
92. Roychowdhury, S. 2006."Earnings Management through Real Activities Manipulation." Journal of Accounting and Economics 42 (3): 335-370. (Pubitemid 44350041)
93. Scherer, F., S. Herzstein, A. Dreyfoos, W. Whitney, O. Bachmann, C. Pesek, C. Scott, T. Kelly, and J. Galvin. 1959. Patents and the Corporation: A Report on Industrial Technology under Changing Public Policy. Boston, MA: JJ Galvin (privately published).
94. Schmalensee, R. 1981. "Economies of Scale and Barriers to Entry." Journal of Political Economy 89 (6): 1228-1238.
95. Seethamraju, C. 2000. "The Value Relevance of Trademarks." Ph.D. diss., New York University.
96. Shah, Z., A. Stark, and S. Akbar. 2008. "The Value-relevance of Major Media Advertising Expenditures: Some UK Evidence." International Journal of Accounting. Forthcoming.
97. Sheffet, M., and S. Kopp. 1990. "Advertising Prescription Drugs to the Public: Headache or Relief?" Journal of Public Policy and Marketing 9(1): 42-61.
98. Simpson, A. 2008. "Voluntary Disclosure of Advertising Expenditures." Journal of Accounting, Auditing, and Finance 23: 403-436.
99. Spence, M., S. Teleki, C. Cheetham, and S. Schweitzer. 2005. "Direct-to-Consumer Advertising of COX-2 Inhibitors: Effect on Appropriateness of Prescribing." Medical Care Research and Review 62 (5): 544-559.
100. Thompson, C. 1998. "Consumer Ads Build Awareness but Not Understand of Advertised Medications, Survey Reveal." American Journal of Health System Pharmacy 55: 2344-2347.
101. Tiróle, J. 1990. The Theory of Industrial Organization. Cambridge, MA: MIT Press.
102. Trowbridge, R., and S. Walker. 2007. "The FDA's Deadly Track Record." Wall Street Journal, August 14, A17.
103. Trueman, B., F. Wong, and X. Zhang. 2000. "The Eyeballs Have It: Searching for Value in Internet Stocks." Journal of Accounting Research 38: 137-162.
104. Weintraub, A. 2007. "Putting Drug Ads Back in the Bottle." Business Week, August 13, 64.
105. Wilkes, M., R. Bell, and R. Kravitz. 2000. "Direct-to-Consumer Prescription Drug Advertising: Trends, Impact, and Implications." Health Affairs 19 (2): 110-127.
106. Zachry, W., M. Shepherd, and M. Hinich. 2002. "Relationship between Direct-to-Consumer Advertising and Physician Diagnosing and Prescribing." American Journal of Health-System Pharmacy. 42-49.